Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting.
about
Serotonin receptor antagonists for highly emetogenic chemotherapy in adultsSerotonin receptor antagonists for highly emetogenic chemotherapy in adultsEnteroendocrine cells: neglected players in gastrointestinal disorders?Management of Chemotherapy Induced Nausea and Vomiting in Patients on Multiday Cisplatin Based Combination ChemotherapySerotonin type 3-receptor antagonists for chemotherapy-induced nausea and vomiting: therapeutically equivalent or meaningfully different?On serotonin and migraine: a clinical and pharmacological reviewPostprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: a pilot studyPharmacokinetics of Tigecycline after Single and Multiple Doses in Healthy SubjectsComparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study. OndansetrStudies on the synthesis, characterization, binding with DNA and activities of two cis-planaramineplatinum(II) complexes of the form: cis-PtL(NH3)Cl2 where L = 3-hydroxypyridine and 2,3-diaminopyridinePhase I/II study of a short course of weekly cisplatin in patients with advanced solid tumoursManaging hyperemesis gravidarum: a multimodal challenge.Peptide targeting of platinum anti-cancer drugsEffect of zatosetron on ipecac-induced emesis in dogs and healthy men.Volunteer models for predicting antiemetic activity of 5-HT3-receptor antagonists.Serotonergic mediation of postprandial colonic tonic and phasic responses in humans.Serotonergic modulation of visceral sensation: lower gut.Pharmacogenetic predictors of nausea and vomiting of pregnancy severity and response to antiemetic therapy: a pilot study.Cisplatin-induced early and delayed emesis in the pigeonComparative pharmacokinetics of cyclophosphamide administration alone and combination with vitamin B6 in rats.New therapies for ovarian cancer.Pharmacology of serotonin: what a clinician should know.Neuropharmacology of emesis in relation to clinical response.Smoking cessation pharmacogenetics: analysis of varenicline and bupropion in placebo-controlled clinical trials.Reduction of carboplatin induced emesis by ondansetron.Treatment with para-chlorophenylalanine antagonises the emetic response and the serotonin-releasing actions of cisplatin in cancer patients.Comparative efficacy of a single oral dose of ondansetron and of buspirone against cisplatin-induced emesis in cancer patientsPlasma chromogranin A marks emesis and serotonin release associated with dacarbazine and nitrogen mustard but not with cyclophosphamide-based chemotherapies5-Hydroxyindoleacetic acid (5-HIAA) and cortisol excretion as predictors of chemotherapy-induced emesisAre more antiemetic trials with a placebo necessary? Report of patient data from randomized trials of placebo antiemetics with cisplatin.Advances in the management of cytotoxic drug-induced nausea and vomiting.Serotonin pharmacology in the gastrointestinal tract: a review.The role of platelet count, mean platelet volume, and the mean platelet volume/platelet count ratio in predicting postoperative vomiting in children after deep sedation.Chemotherapy-induced nausea and vomiting: antiemetic trials that impacted clinical practice.Cisplatin-induced emesis: systematic review and meta-analysis of the ferret model and the effects of 5-HT₃ receptor antagonistsPharmacologic management of postoperative nausea and vomiting.BnRCH gene inhibits cell growth of Hela cells through increasing the G2 phase of cell cycle.The use of ondansetron in the treatment of nausea and vomiting associated with acetaminophen poisoning.Efficacy benefit of an NK1 receptor antagonist (NK1RA) in patients receiving carboplatin: supportive evidence with NEPA (a fixed combination of the NK1 RA, netupitant, and palonosetron) and aprepitant regimens.Phase II study of fosaprepitant + 5HT3 receptor antagonist + dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: a Hoosier Cancer Research Network study.
P2860
Q24202033-DDCA6C58-D4A8-4B1A-8771-6D190845ECD4Q24240511-10A20C05-7C74-4EE8-BDC5-120C4B078F79Q24629026-647BE3E9-37D9-42D3-8BCD-BE3CA1B873CFQ26783177-F0CB526F-F591-4D13-9E13-5B014ED0F1CEQ27000620-12A49829-000A-470A-BCB7-53EFA2DEA3A8Q28263827-D60FD0F5-D674-4D39-B6B9-0389B7AE9C4DQ28379389-EFDCD164-2459-4DD9-8B83-D4DF71F2C7A5Q29398341-C7D670BD-9B6D-48FF-A2BD-EF0E49056F8CQ33190512-CB585B16-8692-4768-859B-1A55081ED393Q33236272-6CFF5EEF-D787-4702-9602-082EC3C7EAACQ33494110-4D1A920B-E409-47D3-AE4D-3BC960D218D1Q33633388-CFD89650-9A28-44F6-9993-9CFA1DAA6788Q33937941-07EFE176-C5E7-4C34-A6B0-D49ABF06E7A3Q34291981-E7300D4E-8461-419A-88C1-17FD614874D5Q34346342-320289DB-45EB-4916-97D8-5EFE6DC1A20EQ34378949-61382143-FAE4-4DAC-A6C4-6771CBD9AE5BQ34699859-7DAC3209-4E1C-438A-BEBA-6150386BB6ABQ34779394-72202C6A-F956-4403-992A-22AE62EEE3DBQ35042209-7924A826-D923-4C62-9686-ECFC8FB596F1Q35166504-D70790F8-5789-498D-921C-37995CD49BA8Q35259954-8E5E2AF3-4B2C-4BBF-971E-576F7E932D08Q35596862-385C28E4-F40D-4537-B0E7-40294D3AC2F4Q35606492-F934A54D-68F2-4C15-9C97-4D1A4A5C1F95Q35679980-7A69BB3A-D3A3-4675-9F86-93CE64BB23C3Q35984723-8E2AA9C7-65DF-4306-875B-5E079FAB389CQ36080511-8C11B10F-AD5A-4825-80A6-CDDA7F9A0483Q36081699-80C9C5C8-365D-4617-BF44-ED3B59ABE146Q36081722-92731772-D57D-4C18-B3C0-5E6E46651AF5Q36141026-D689475B-FC36-4118-B907-93E4FEFB79C2Q36832481-6831E812-6164-4DA4-929F-FAAA4FFBADC3Q36911183-9E45B024-1068-479C-AF0B-47E5560C1032Q37132811-4B742E41-884E-4783-9536-18EE2F809D27Q37359231-B49C4312-CFA4-4274-BE09-D4501E5A3787Q37677897-B72E2D87-95D4-4526-A932-866D06D9560FQ37761329-82504FD6-30FA-4CC9-BCB2-47C3CBB65318Q37901057-4858B222-DA55-4111-A55B-4170A06362C5Q39450806-4EBE18CD-5851-4508-BF8B-F60B76AC4A80Q39469615-214E05EC-CDB5-4907-8897-F004AB3063DEQ39662535-5956702F-29F0-4C1A-A882-D2C97C27761BQ40030462-13A7AE44-1F56-4CAD-B091-3176AC255019
P2860
Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting.
description
1990 nî lūn-bûn
@nan
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
1990年论文
@zh
1990年论文
@zh-cn
name
Efficacy of ondansetron (GR 38 ...... n-induced nausea and vomiting.
@en
Efficacy of ondansetron
@nl
type
label
Efficacy of ondansetron (GR 38 ...... n-induced nausea and vomiting.
@en
Efficacy of ondansetron
@nl
prefLabel
Efficacy of ondansetron (GR 38 ...... n-induced nausea and vomiting.
@en
Efficacy of ondansetron
@nl
P2093
P1476
Efficacy of ondansetron (GR 38 ...... n-induced nausea and vomiting.
@en
P2093
Cubeddu LX
Fuenmayor NT
Hoffmann IS
P304
P356
10.1056/NEJM199003223221204
P407
P577
1990-03-01T00:00:00Z